When you first think of the words domination and excellence, you’re probably associating this notion with sports. Fortunately, this notion is referring to the advancements in medicine. Cancer is all too prevalent in society now days. This deadly disease can affect many different organs in the body no matter the age, race, or creed of an individual. It may seem to be hopeless if you’re not caught up on current events, but there have been many advancements in this field over the past decade and there is one company that’s leading the way.
Seattle Genetics of Bothell, Washington is turning the tide and the fight against dangerous cancer. The company has been around since the late 90’s and is one of the most progressive thinking and acting Bio-Technology Institutions in the world. This bio-technology company is focused on developing and commercializing antibody based therapies that deal with the specifics of cancer. Their (ADCs) Antibody Drug Conjugates are specifically designed to neutralize and deliver cell-killing agents directly in cancerous cells. It’s like the old saying, ” you have to cut the snake’s head off to completely kill it.” That notion rings true the company’s (ADCs) as they are some of the researched most pharmaceuticals on the planet. Another bonus of these ” cancer cell killers” is that the patient shouldn’t experience any ill side effects from the treatments unlike Chemotherapy. The company has a continued approach to remaining the best in an industry that’s full of hopes and dreams. The future seems to be looking bright as Seattle Genetics has many new products and projects in the pipeline. To have such a strong presence and success, you have to have a strong leader and Seattle Genetics’ Dr. Clay Siegell is leading this brand through the 21st Century. The highly accomplished doctor/scientist has up to 20 years in cancer development and research as well as worked for numerous prominent industry leading corporations.
The future is now and Seattle Genetics is leading the way in the fight against deadly cancerous diseases.
Learn more about Clay Siegall: